Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBIT plus low-dose tiapride vs standard-dose tiapride for children with tic disorders
ChiCTR2600117177Phase 4Recruiting
- Sponsor
- Beilun District People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tiapride in tic disorder (2 arms), sponsored by Beilun District People's Hospital. Primary endpoints: Improve target symptoms and Improve the total clinical effective rate. Started Jan 2026; status: recruiting.
02
Drugs
tiapride
03
Conditions
tic disorder
Beyond the preview
Go deeper on ChiCTR2600117177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117177.